WHO Issues Alert Over Critical Scarcity of Obesity Medications
Fewer than one in 10 patients who could benefit from GLP-1 drugs including Wegovy have access to them, warns the WHO as it issues its initial recommendations on the therapies.
Given over a billion individuals worldwide currently classified as obese, it is urging broader and more equitable availability to GLP-1 medication.
Based on forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"The latest guidance recognises that obesity is a long-term condition that can be treated with holistic and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are key barriers to widespread availability to the injections that can help people shift substantial weight, explains the body.
Weight-Loss Drug Supply Crisis
Even under the present most favorable case, the manufacturing of these medications could only cover about 100 million people – under 10% of those who need them, as stated by the health organization.
The advice urges nations and manufacturers to increase availability, via measures such as patent sharing.
The intellectual property rights on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs mimick a natural hormone to slow digestion, curb appetite and boost feelings of fullness so individuals reduce food intake.
Patients usually start to lose weight within a few weeks of commencing the weekly injections.
Evidence suggests users may regain a significant portion a year later of stopping the treatment, because their normal hunger return.
To be carrying excess weight elevates your likelihood for developing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity affects individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.
